283 related articles for article (PubMed ID: 12666098)
1. Neuroinflammatory processes in Parkinson's disease.
Hunot S; Hirsch EC
Ann Neurol; 2003; 53 Suppl 3():S49-58; discussion S58-60. PubMed ID: 12666098
[TBL] [Abstract][Full Text] [Related]
2. Loss of dopaminergic neurons by the induction of inducible nitric oxide synthase and cyclooxygenase-2 via CD 40: relevance to Parkinson's disease.
Okuno T; Nakatsuji Y; Kumanogoh A; Moriya M; Ichinose H; Sumi H; Fujimura H; Kikutani H; Sakoda S
J Neurosci Res; 2005 Sep; 81(6):874-82. PubMed ID: 16041799
[TBL] [Abstract][Full Text] [Related]
3. Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2.
Knott C; Stern G; Wilkin GP
Mol Cell Neurosci; 2000 Dec; 16(6):724-39. PubMed ID: 11124893
[TBL] [Abstract][Full Text] [Related]
4. Neuroinflammatory processes in Parkinson's disease.
Hirsch EC; Hunot S; Hartmann A
Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S9-S15. PubMed ID: 15885630
[TBL] [Abstract][Full Text] [Related]
5. Thrombin-activated microglia contribute to death of dopaminergic neurons in rat mesencephalic cultures: dual roles of mitogen-activated protein kinase signaling pathways.
Lee DY; Oh YJ; Jin BK
Glia; 2005 Aug; 51(2):98-110. PubMed ID: 15789435
[TBL] [Abstract][Full Text] [Related]
6. JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease.
Hunot S; Vila M; Teismann P; Davis RJ; Hirsch EC; Przedborski S; Rakic P; Flavell RA
Proc Natl Acad Sci U S A; 2004 Jan; 101(2):665-70. PubMed ID: 14704277
[TBL] [Abstract][Full Text] [Related]
7. Catalpol protects dopaminergic neurons from LPS-induced neurotoxicity in mesencephalic neuron-glia cultures.
Tian YY; An LJ; Jiang L; Duan YL; Chen J; Jiang B
Life Sci; 2006 Dec; 80(3):193-9. PubMed ID: 17049947
[TBL] [Abstract][Full Text] [Related]
8. Pathogenesis of nigral cell death in Parkinson's disease.
Przedborski S
Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S3-7. PubMed ID: 15885625
[TBL] [Abstract][Full Text] [Related]
9. Dopaminergic neurotoxicity by 6-OHDA and MPP+: differential requirement for neuronal cyclooxygenase activity.
Carrasco E; Casper D; Werner P
J Neurosci Res; 2005 Jul; 81(1):121-31. PubMed ID: 15931668
[TBL] [Abstract][Full Text] [Related]
10. Parkinson's disease: clinical aspects.
Klockgether T
Cell Tissue Res; 2004 Oct; 318(1):115-20. PubMed ID: 15365814
[TBL] [Abstract][Full Text] [Related]
11. Toward full restoration of synaptic and terminal function of the dopaminergic system in Parkinson's disease by stem cells.
Isacson O; Bjorklund LM; Schumacher JM
Ann Neurol; 2003; 53 Suppl 3():S135-46; discussion S146-8. PubMed ID: 12666105
[TBL] [Abstract][Full Text] [Related]
12. Neuroinflammation - A major cause for striatal dopaminergic degeneration in Parkinson's disease.
Kaur K; Gill JS; Bansal PK; Deshmukh R
J Neurol Sci; 2017 Oct; 381():308-314. PubMed ID: 28991704
[TBL] [Abstract][Full Text] [Related]
13. Andrographolide reduces inflammation-mediated dopaminergic neurodegeneration in mesencephalic neuron-glia cultures by inhibiting microglial activation.
Wang T; Liu B; Zhang W; Wilson B; Hong JS
J Pharmacol Exp Ther; 2004 Mar; 308(3):975-83. PubMed ID: 14718612
[TBL] [Abstract][Full Text] [Related]
14. Nitric oxide synthase and neuronal vulnerability in Parkinson's disease.
Hunot S; Boissière F; Faucheux B; Brugg B; Mouatt-Prigent A; Agid Y; Hirsch EC
Neuroscience; 1996 May; 72(2):355-63. PubMed ID: 8737406
[TBL] [Abstract][Full Text] [Related]
15. Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration.
Morale MC; Serra PA; L'episcopo F; Tirolo C; Caniglia S; Testa N; Gennuso F; Giaquinta G; Rocchitta G; Desole MS; Miele E; Marchetti B
Neuroscience; 2006; 138(3):869-78. PubMed ID: 16337092
[TBL] [Abstract][Full Text] [Related]
16. [Inflammation and Parkinson's disease].
Barcia González C; Herrero Ezquerro MT
Rev Neurol; 2004 Mar 16-31; 38(6):545-53. PubMed ID: 15054720
[TBL] [Abstract][Full Text] [Related]
17. The degeneration of dopamine neurons in Parkinson's disease: insights from embryology and evolution of the mesostriatocortical system.
Vernier P; Moret F; Callier S; Snapyan M; Wersinger C; Sidhu A
Ann N Y Acad Sci; 2004 Dec; 1035():231-49. PubMed ID: 15681811
[TBL] [Abstract][Full Text] [Related]
18. Neuroinflammation in Parkinson's disease: a target for neuroprotection?
Hirsch EC; Hunot S
Lancet Neurol; 2009 Apr; 8(4):382-97. PubMed ID: 19296921
[TBL] [Abstract][Full Text] [Related]
19. Role of p38 and inducible nitric oxide synthase in the in vivo dopaminergic cells' degeneration induced by inflammatory processes after lipopolysaccharide injection.
Ruano D; Revilla E; Gavilán MP; Vizuete ML; Pintado C; Vitorica J; Castaño A
Neuroscience; 2006 Jul; 140(4):1157-68. PubMed ID: 16713109
[TBL] [Abstract][Full Text] [Related]
20. Cellular pathology of Parkinson's disease: astrocytes, microglia and inflammation.
Teismann P; Schulz JB
Cell Tissue Res; 2004 Oct; 318(1):149-61. PubMed ID: 15338271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
